LeMaitre Vascular, Inc. (NASDAQ:LMAT) updated its third quarter earnings guidance on Thursday. The company provided EPS guidance of $0.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.17. The company issued revenue guidance of $25.4 million, compared to the consensus revenue estimate of $24.84 million.LeMaitre Vascular also updated its FY17 guidance to $0.79 EPS.
A number of equities research analysts recently commented on the company. Benchmark Co. raised LeMaitre Vascular from a hold rating to a buy rating in a report on Friday. BidaskClub downgraded LeMaitre Vascular from a strong-buy rating to a buy rating in a report on Tuesday. Canaccord Genuity downgraded LeMaitre Vascular from a buy rating to a hold rating and set a $28.00 target price for the company. in a report on Monday, July 10th. Zacks Investment Research downgraded LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, July 4th. Finally, Craig Hallum assumed coverage on LeMaitre Vascular in a report on Tuesday, June 6th. They set a hold rating and a $31.00 target price for the company. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $27.00.
Shares of LeMaitre Vascular, Inc. (LMAT) traded up 19.51% on Friday, reaching $33.94. The company’s stock had a trading volume of 859,710 shares. The company has a market capitalization of $638.38 million, a price-to-earnings ratio of 56.66 and a beta of 0.63. The stock has a 50-day moving average price of $29.44 and a 200-day moving average price of $26.65. LeMaitre Vascular, Inc. has a 1-year low of $16.38 and a 1-year high of $35.24.
LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, May 4th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.03. LeMaitre Vascular had a return on equity of 13.36% and a net margin of 12.52%. The company had revenue of $24.10 million during the quarter, compared to analysts’ expectations of $23.48 million. The firm’s revenue was up 18.7% compared to the same quarter last year. On average, equities research analysts forecast that LeMaitre Vascular, Inc. will post $0.70 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Wednesday, August 23rd will be given a dividend of $0.055 per share. The ex-dividend date of this dividend is Monday, August 21st. This represents a $0.22 dividend on an annualized basis and a yield of 0.65%. LeMaitre Vascular’s payout ratio is 36.67%.
LeMaitre Vascular announced that its board has authorized a share repurchase program on Thursday, July 27th that authorizes the company to buyback $7.50 million in shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 1.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.
In other LeMaitre Vascular news, VP Michael T. Wijas sold 2,346 shares of the stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $31.42, for a total transaction of $73,711.32. Following the completion of the sale, the vice president now directly owns 3,584 shares of the company’s stock, valued at approximately $112,609.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman George W. Lemaitre sold 87,342 shares of the stock in a transaction that occurred on Wednesday, May 3rd. The stock was sold at an average price of $32.35, for a total value of $2,825,513.70. Following the sale, the chairman now directly owns 3,484,149 shares of the company’s stock, valued at $112,712,220.15. The disclosure for this sale can be found here. Insiders have sold a total of 317,805 shares of company stock valued at $9,910,332 over the last ninety days. 23.70% of the stock is owned by insiders.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
